CEO Executive AssistantGastrointestinal disease is having a pharmaceutical moment unlike anything the field has seen. The IBD biologics market, anchored for years by TNF inhibitors, has fractured into a multi-mechanism competitive environment with integrin inhibitors, IL-12/23 blockers, IL-23 selective agents, JAK inhibitors, and a growing class of S1P receptor modulators all competing for the same Crohn’s disease and ulcerative colitis patients. The microbiome is transitioning from basic science curiosity to clinical-stage asset class. And specialty pharmacy access barriers have made commercial execution in GI one of the most operationally demanding challenges in biopharma.
For the pharma CEO managing a GI portfolio, this complexity demands a level of time management discipline that goes well beyond general executive productivity principles. This article provides a direct framework for how to allocate your time, where CEO-level attention drives outsized returns, and how to avoid the failure modes that have derailed otherwise well-positioned GI companies.
The Structural Complexity of the GI Competitive Landscape
Before addressing time allocation, it is worth being precise about what makes GI so demanding from a leadership standpoint.
IBD affects roughly 3 million Americans, with Crohn’s disease and ulcerative colitis accounting for the largest patient populations. These are chronic, relapsing conditions with significant unmet need despite the expansion of approved therapies: a meaningful proportion of patients fail on first-line biologics and cycle through multiple agents. This treatment failure reality drives ongoing clinical development activity and ensures that new mechanisms continue to enter the market.
The commercial implications are significant. Unlike therapeutic areas where a single dominant agent has captured most of the addressable market, GI biologics remains genuinely contested. Prescribing gastroenterologists make nuanced decisions based on disease phenotype, prior therapy history, comorbidities, and patient preference. The CEO who understands this clinical texture can make better decisions about indication strategy, clinical trial design, and the commercial positioning of new agents.
The specialty pharmacy and prior authorization environment adds a layer of operational complexity that is often underestimated by executives coming from other therapeutic areas. Prior authorization approval rates, time-to-therapy metrics, and specialty pharmacy fill rates are the commercial execution variables that determine whether a successful launch turns into a durable revenue stream or stalls after initial uptake.
Where CEO Time Creates Strategic Value in GI
Shaping the Commercial Access Architecture
The single most common commercial failure mode in GI biologics is underestimating the prior authorization burden and failing to build the organizational infrastructure to manage it proactively. Prior authorization denial rates for new GI biologics can be substantial, particularly in the first 12 to 24 months post-launch when payers are still formulating their coverage policies.
CEOs who treat this as an operational detail rather than a strategic priority pay for it in revenue underperformance. The right approach is to engage directly with your market access leadership on the architecture of your payer strategy before launch, not after. This means understanding which payers cover your target patient population, what their step therapy criteria look like, what clinical evidence they require to approve coverage, and what your contracting strategy will be.
It also means understanding how your specialty pharmacy partners are performing. GI biologics flow through a concentrated set of specialty pharmacies, and the quality of the patient services infrastructure these pharmacies provide directly affects adherence and outcomes. CEOs who invest time in these commercial access questions build commercial machines that can actually deliver the revenue their pipelines promise.
Your market access strategy decisions set the trajectory for every product in your portfolio, and they require the CEO’s active engagement rather than periodic check-ins.
Engaging the Patient Advocacy Community
The GI patient advocacy community is unusually sophisticated and well-organized. The Crohn’s and Colitis Foundation (formerly CCFA) has been a consistent force in shaping research priorities, payer policies, and patient engagement standards in IBD. Smaller advocacy organizations focused on IBS, eosinophilic GI diseases, and rare GI conditions are also active and well-connected.
These organizations matter to a GI portfolio CEO for several reasons. They are credible interlocutors with payers and policymakers on coverage and access issues. They have direct relationships with the patient communities your products serve and can provide feedback on real-world disease burden that your clinical development program may not fully capture. They also have meaningful influence over prescriber perceptions, particularly among academic gastroenterologists who participate in advocacy-funded research initiatives.
The mistake many CEOs make is treating patient advocacy relationships as a corporate communications function. The communications team manages the press releases and the donation agreements. But the strategic relationship, the one where you are discussing unmet needs, research priorities, and the patient experience with a product in development, belongs at the CEO level.
Invest time in one or two substantive engagements with key GI patient advocacy organizations each year. Be present personally, not represented by your communications or medical affairs team alone. The relationships you build will pay dividends in clinical trial recruitment, real-world evidence generation, and payer advocacy over the lifecycle of your products.
Positioning for the Microbiome Opportunity
The microbiome therapeutic space is moving from exploratory to executable. FMT-derived therapies for recurrent C. difficile infection have reached approval. Rationally designed microbiome consortia are in Phase 2 development for IBD, metabolic disease, and other indications. The clinical logic connecting gut microbial dysbiosis to IBD pathophysiology is well-established, and several well-funded companies are advancing assets that could reach proof-of-concept within the next three to five years.
For a GI portfolio CEO, the microbiome represents both an opportunity and a positioning question. If your portfolio is anchored in approved biologics with patent cliffs approaching, microbiome assets offer a pathway to pipeline renewal. If you are a development-stage company, the microbiome space is becoming credible enough to be relevant to business development conversations with larger partners.
The CEO’s role is not to become a microbiome scientist. It is to ensure that your organization has a clear and defensible point of view on the microbiome landscape: where it is in its development arc, which technical approaches are most credible, and what role it should play in your portfolio strategy. This requires time spent with your scientific advisory board, your chief scientific officer, and external experts who can provide unbiased assessments of the competitive dynamics.
According to McKinsey’s research on biopharma innovation cycles, therapeutic areas that experience genuine mechanism diversification create disproportionate value for companies that position early in emerging modalities. The GI microbiome is precisely this kind of inflection point.
Building the Gastroenterology KOL Network
Gastroenterology, like dermatology, has a relatively concentrated prescriber base for specialty biologics. Academic gastroenterologists at major IBD centers prescribe a disproportionate share of biologic volume and exert significant influence over community prescribing patterns through publications, guidelines, and speaking engagements.
CEO-level relationships with leading gastroenterologists serve multiple strategic functions. These clinicians provide direct feedback on clinical trial design, unmet need characterization, and competitive positioning that is often more candid and clinically specific than what your commercial team hears through standard market research. They are also frequently involved in guideline development and payer advisory processes where their perspective on your product can influence coverage decisions.
The discipline here, as in dermatology, is selectivity. Identify the 10 to 15 gastroenterologists whose clinical perspective genuinely shapes your development and commercial decisions. Invest in those relationships personally. Let your medical science liaison network manage the broader prescriber universe.
Attendance at Digestive Disease Week (DDW) and United European Gastroenterology Week (UEGW) should be non-negotiable for a GI portfolio CEO, not for the scientific sessions alone but for the relationship-building and competitive intelligence that happen in the corridors and dinner conversations around these conferences.
Governing the Pipeline with Commercial Discipline
GI drug development has a history of late-stage failures that could have been anticipated with more rigorous competitive analysis at the program entry decision point. The failure to differentiate from existing biologics on clinically meaningful endpoints, the selection of patient populations that are already well-served by approved agents, and the under-investment in biomarker-driven patient selection have each contributed to expensive late-stage programs that did not succeed.
CEOs who apply commercial discipline to pipeline governance decisions, asking not only whether a mechanism can produce clinical response but whether the clinical profile will be competitive in the market that will exist at the time of approval, dramatically improve their pipeline productivity.
Rigorous lifecycle management strategy thinking should be built into every program entry decision, not retrofitted after approval. In a competitive GI market, the decision to pursue a specific IBD indication with a specific clinical development program is a commercial strategy decision as much as a scientific one.
Time Allocation: A Practical Framework for GI Portfolio CEOs
Commercial and Market Access (25 to 30 Percent)
This is a higher allocation than many CEOs are comfortable with, particularly those who come from scientific or clinical backgrounds. But in GI, where prior authorization burden and specialty pharmacy execution are commercial rate-limiters, the CEO who is not fluent in market access dynamics will consistently underestimate commercial obstacles and overestimate revenue forecasts.
This block includes quarterly market access reviews, specialty pharmacy performance monitoring, managed care account strategy, and the pricing and contracting decisions that determine your gross-to-net economics.
Pipeline and R&D Governance (25 Percent)
GI pipeline decisions are high-stakes and require the CEO’s direct engagement. Clinical trial design in IBD is complex: endpoint selection, patient population definitions, and the use of biomarkers to enrich patient populations all have significant implications for both development success probability and commercial positioning. CEOs who are not active participants in these discussions often inherit programs that are scientifically interesting but commercially problematic.
External Stakeholder Engagement (20 Percent)
This encompasses patient advocacy relationships, KOL engagement, regulatory interactions, conference participation, and the business development conversations that could yield partnership or acquisition opportunities. In GI, where the patient advocacy organizations are particularly influential and the academic gastroenterology community is relatively small and well-connected, this allocation is well-invested.
Investor Relations and Capital Strategy (15 Percent)
GI biologics and microbiome development programs are capital-intensive. The competitive landscape makes it harder to justify capital allocation to programs without clear differentiation stories. CEOs who spend meaningful time maintaining investor relationships and communicating a credible differentiation strategy are better positioned to access capital efficiently when they need it.
Organizational Leadership (10 to 15 Percent)
Building commercial, medical, and regulatory teams with GI expertise is genuinely hard. The specialty pharmacy and market access complexity in GI requires commercial talent with specific experience navigating this environment. CEOs who invest in hiring and retaining this talent differentiate their organizations from those that treat GI as a generic specialty biopharma problem.
The Prior Authorization Problem Deserves CEO Attention
Prior authorization in GI biologics deserves specific attention because it is so consistently underestimated. The process by which payers approve biologic therapy for IBD patients involves step therapy requirements (often requiring TNF inhibitor failure before access to newer mechanisms), clinical documentation requirements, and periodic re-authorization cycles that create ongoing access barriers.
The commercial impact is real and measurable. Studies have found that prior authorization delays in GI can result in disease progression, hospitalization, and patient abandonment of treatment initiation. These outcomes harm patients and erode the commercial potential of products that are clinically effective but access-constrained.
CEOs who understand this dynamic invest in patient support programs with dedicated prior authorization navigation support, build data collection systems that can document prior therapy history and disease severity to support authorization requests, and engage proactively with payers on the clinical evidence that should govern their authorization criteria.
This is not glamorous work, but it is the work that separates high-performing GI commercial organizations from those that underperform against their potential.
Competitive Positioning in a Multi-Mechanism Market
The IBD biologics market of 2026 is more complex than the market that TNF inhibitors dominated a decade ago. Gastroenterologists now have access to agents across multiple mechanisms and must make sequencing decisions that account for safety profiles, mechanism of action, route of administration, and prior therapy history. New entrants need to be clear about where in this treatment paradigm they fit and for which patient populations their profile represents the best option.
CEOs leading GI companies need a crisp competitive positioning framework that goes beyond general differentiation claims. Which patient populations are currently underserved by approved agents? Where does your clinical profile suggest meaningful efficacy advantages? What safety attributes matter most to gastroenterologists in the specific treatment settings you are targeting?
These questions have specific, data-driven answers that should inform your commercial strategy, your clinical trial design, and your medical affairs evidence generation priorities. CEOs who can articulate this positioning with clarity create organizations that execute with purpose rather than with generic specialty biopharma playbooks.
Building for Durability in GI
The GI space rewards long-term thinking. Products with strong clinical profiles and robust patient support infrastructure build durable patient populations: IBD is a chronic disease, and patients who achieve remission on a biologic tend to remain on it for years. The commercial lifetime value of a well-supported IBD patient significantly exceeds what a single-year revenue snapshot suggests.
CEOs who build organizations designed for long-term patient retention, investing in real-world evidence generation, patient support infrastructure, and the payer relationships that maintain formulary access over time, build companies with more predictable revenue and stronger negotiating positions with acquirers and partners.
The GI competitive landscape will continue to intensify. New mechanisms will emerge. Biosimilar competition will erode margins in the TNF inhibitor segment and eventually in newer classes. The microbiome will deliver its first commercial successes and create new competitive dynamics. Through all of this, the CEOs who have built strong organizational capabilities, robust payer relationships, and genuine patient advocacy partnerships will have the strategic assets to navigate change rather than being disrupted by it.
Time management in GI is ultimately about building those assets systematically, quarter by quarter, through deliberate choices about where your personal attention goes and where you trust your organization to execute. The framework described here is a starting point. The discipline to apply it consistently is what separates the leaders who win in this space from those who manage toward a competitive average.